Effects of salt substitute on blood pressure among patients with stage G2 or G3a chronic kidney disease: The ECLIPSE-CKD randomized controlled trial

Summarise with VIRAT
Authors: Dong Shui, Xinyi Zhang, Maoyi Tian, Wei Tian, Bruce Charles Neal, Xiong Ding
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ECLIPSE-CKD trial is a multi-center, open-label, prospective randomized controlled trial, conducted in seven counties, across two Chinese provinces (Heilongjiang and Hubei). Participants in the intervention group receive free salt substitute, produced according to the national standard (QB/T 2019-2020), to replace all regular salt used for cooking, seasoning, and food preservation for 3 months, whereas participants in the control group continue to use regular salt. The primary efficacy outcome for the ECLIPSE-CKD trial is the change of systolic blood pressure from baseline to month 3. The secondary efficacy outcomes are the change of diastolic blood pressure and serum potassium level from baseline to month 3. The primary safety outcome is the number of participants with hyperkalemia. The other safety outcomes include number of hypokalemia events, hospitalizations for any cause, and death from any cause.

Fields of Study & Subjects

Sodium Intake and Health Blood Pressure and Hypertension Studies Dialysis and Renal Disease Management

Publication details

Journal / source
OSF Preprints (OSF Preprints)
Publication date
23 March 2026
Language
EN
Document type
Preprint